帕利哌酮缓释剂治疗首发、复发精神分裂症患者的临床疗效以及对患者社会功能改善的作用

The clinical efficacy and the improvement of social function in patients with first-episode and recurrent schizophrenia treated with Paley

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2017, 44(3)
作者
作者单位

武汉大学人民医院精神卫生中心 ;
.武汉市武东医院 ;

摘要
【摘要】目的:探讨帕利哌酮缓释剂治疗首发、复发精神分裂症患者的临床疗效以及对患者社会功能改善的作用观察。方法:选取2014年1月至2016年1月期间首次在我院接受治疗的20例精神分裂症患者(首发组)和复发再次入院接受治疗的20例精神分裂症患者(复发组)作为本研究对象,两组患者均采用帕利哌酮缓释剂进行治疗。分别对两组患者的治疗前、治疗2周、4周和8周后的阴性与阳性症状量表(PANSS)、治疗前后的社会功能改善(PSP总分)、临床疗效以及药物不良反应的发生率进行比较。结果:经比较,两组患者PANSS量表评分差异无统计学意义(P>0.05),治疗2周、4周和8周后,首发组患者间的PANSS总分、阴性症状、阳性症状及一般病理量表评分较治疗前降低,差异显著(P<0.05),而复发组患者的PANSS总分、阳性症状及一般病理量表评分亦比治疗前低(P<0.05),而阴性症状治疗2周时差异不明显,但在治疗4周后差异有统计学意义(P<0.05);经比较,两组患者治疗8周后的PSP总分与治疗前差异有统计学意义(P<0.05),两组间比较差异无统计学意义(P>0.05),但首发组的总分更高于于复发组;首发组和复发组相比较,前者的临床显效率和不良反应总发生率与后者间差异无统计学意义(P>0.05)。结论:帕利哌酮缓释剂治疗首发、复发精神分裂症患者的阴阳性症状的疗效较为显著,且具有一定的安全性,同时可以在一定的程度上提高患者的社会功能,因而值得临床推广应用。
Abstract
【Abstract】Objective: To investigate the clinical efficacy of Paleys slow release agent in the treatment of first-episode and recurrent schizophrenia and the improvement of social function. Methods: from January 2014 to January 2016 for the first time in our hospital for treatment of 20 cases of schizophrenia patients (the first group) and the recurrence of the hospital for treatment of 20 cases of schizophrenia patients (recurrence group) as the research object, two groups of patients were treated with risperidone sustained-release agent Paley treatment. The two groups of patients were treated with Paley. Respectively in the two groups of patients before treatment, 2 weeks, 4 weeks and 8 weeks with positive and negative symptoms scale (PANSS) before and after treatment, social function (PSP score), clinical efficacy and incidence of adverse drug reactions were compared. Results: by comparison, the scores of PANSS of two groups had no significant difference (P>0.05), 2 weeks, 4 weeks and 8 weeks after treatment, the first group of patients between the scores of PANSS, positive symptoms, negative symptoms and general pathology score lower than before treatment, the difference was significant (P<0.05), And the recurrence group of patients with PANSS score, positive symptoms and general pathology scores than before treatment (P<0.05), low and negative symptoms after 2 weeks of treatment, no significant difference, but the difference in the treatment of 4 weeks was statistically significant (P<0.05); Comparison of two groups of patients with total score of PSP after 8 weeks of treatment there were significant differences before (P<0.05), there was no significant difference between the two groups (P>0.05), but the first group was higher than that in total recurrence group; the first group and recurrence group compared the clinical effective rate and adverse reaction of the total there was no significant difference between the latter and (P>0.05). Conclusion: significant efficacy of risperidone sustained-release agent Paley treatment of first-episode and recurrent schizophrenic patients with positive and negative symptoms, and has a certain degree of security, and can improve the patients social function to a certain extent, so it is worthy of clinical application.
关键词
【关键词】:首发精神分裂症;复发精神分裂症;帕利哌酮;临床疗效
KeyWord
【Key words】first episode schizophrenia; recurrent schizophrenia; Paley; clinical efficacy
基金项目
页码 420-422
  • 参考文献
  • 相关文献
  • 引用本文

赵孟,王高华*,陈婷婷,刘毅,陈婕. 帕利哌酮缓释剂治疗首发、复发精神分裂症患者的临床疗效以及对患者社会功能改善的作用 [J]. 国际精神病学杂志. 2017; 44; (3). 420 - 422.

  • 文献评论

相关学者

相关机构